BioSpace News Archive

Coya Therapeutics, Inc. announced that it has appointed Hideki Garren, M.D., Ph.D., Chief Medical Officer of Prothena and Dov Goldstein, M.D., Chief Financial Officer and Chief Business Officer of Indapta, to the Company’s Board of Directors, effective immediately.

Synthetic Biologics, Inc., a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal diseases in areas of high unmet need, announced enrollment has commenced and the first patient has been dosed in its Phase 1b/2a clinical trial of SYN-004 in allogeneic hematopoietic cell transplant recipients for the prevention of acute graft-versus-host-disease.

AnemoCheck Mobile is the first app of its kind to offer patients a remote screening option for anemia, without the need for a blood test

Drug development leader brings extensive expertise in clinical and overall development strategy and execution across a wide range of therapeutic areas

BioAge Labs, Inc. a biotechnology company developing medications that target the molecular causes of aging to extend healthy human life, announced that it has entered into an exclusive worldwide license agreement with Amgen, Inc.

Alpha-synuclein Directed Therapies May Have Utility in Parkinson’s Disease and Related Neurological Disorders, Which Represent a Significant Unmet Medical Need

PsiOxus Therapeutics, Ltd., a clinical stage oncology company re-programming the tumor microenvironment to overcome the central challenge of resistance to therapy, and bluebird bio, Inc. presented preclinical data at the American Association for Cancer Research Annual Meeting 2021.

New Long-Term Follow-Up Data Demonstrate Durable CD18 Expression, Improved Skin Lesions, and Consistent Peripheral Vector Copy Numbers Up to 18-Months Post-Treatment

Castle Biosciences, Inc., a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, announced data from an independent, prospective study published in the American Journal of Surgery demonstrating DecisionDx®-Melanoma’s utility for prediction of outcomes in patients with cutaneous melanoma.

Theratechnologies Inc. (Theratechnologies, or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results for the first quarter ended February 28, 2021 (Q1 Fiscal 2021).